1. Case report: Durable response to afatinib in a patient with lung cancer harboring two uncommon mutations of EGFR and a KRAS mutation.
- Author
-
Tanizaki, Junko, Banno, Eri, Togashi, Yosuke, Hayashi, Hidetoshi, Sakai, Kazuko, Takeda, Masayuki, Kaneda, Hiroyasu, Nishio, Kazuto, and Nakagawa, Kazuhiko
- Subjects
- *
PROTEIN-tyrosine kinase inhibitors , *LUNG cancer treatment , *EPIDERMAL growth factor receptors , *GENETIC mutation , *ANTINEOPLASTIC agents , *THERAPEUTICS - Abstract
Comprehensive genomic profiling for non–small cell lung cancer (NSCLC) is likely to identify more patients with rare genetic alterations including uncommon epidermal growth factor receptor gene ( EGFR ) mutations. It remains unclear how such patients should be treated, however. We here report a case of NSCLC positive for two uncommon mutations of EGFR and a KRAS mutation, including its treatment with the second-generation EGFR tyrosine kinase inhibitor (TKI) afatinib. Tumor specimen obtained by a NSCLC patient with no smoking history was analyzed by next-generation sequencing. Comprehensive genomic profiling revealed that the patient harbored the EGFR mutations G719C and S768I as well as the E49K mutation of KRAS . Treatment with afatinib was clinically effective as confirmed by PET-CT scans of bone metastases and by a marked decrease in the serum concentration of carcinoembryonic antigen. Afatinib was the most effective among seven EGFR-TKIs tested in inhibiting the growth of Ba/F3 cells expressing EGFR(S768I), showing an efficacy similar to that apparent with cells expressing the common EGFR mutant L858R, whereas first- and third-generation EGFR-TKIs were markedly less effective against EGFR(S768I) than against EGFR(L858R). These data suggest that EGFR-TKIs differ in their activity toward cells expressing EGFR(S768I) in vitro. Consistently, afatinib was clinically effective for the treatment of NSCLC harboring G719C and S768I mutations of EGFR . Further studies are warranted to determine the most appropriate EGFR-TKI for treatment of NSCLC harboring uncommon EGFR mutations. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF